Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

BACKGROUND: Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Mahshid, Vaezi, Amir Abbas, Aliannejad, Rasoul, Sohrabpour, Amir Ali, Kiaei, Seyedeh Zahra Fotook, Shadnoush, Mahdi, Siavashi, Vahid, Aghaghazvini, Leila, Khoundabi, Batoul, Abdoli, Shahriyar, Chahardouli, Bahram, Seyhoun, Iman, Alijani, Neda, Verdi, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283394/
https://www.ncbi.nlm.nih.gov/pubmed/34271988
http://dx.doi.org/10.1186/s13287-021-02483-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283394/
https://www.ncbi.nlm.nih.gov/pubmed/34271988
http://dx.doi.org/10.1186/s13287-021-02483-7

Ejemplares similares